PBM Reform Signals the Future — But Employers and Brokers Don’t Have to Wait 

The passage of the Consolidated Appropriations Act (CAA) of 2026 represents one of the most significant federal moves toward pharmacy benefit manager (PBM) transparency in recent years. For employers, brokers, HR leaders, and executive teams who have struggled to understand the true drivers behind rising pharmacy spend, the legislation reinforces a growing industry consensus: 

Transparency is no longer optional. It’s becoming the expected standard. 

Yet one critical reality deserves equal attention. 

Most PBM reform provisions are not expected to take effect for roughly 30 months after enactment. 

In practical terms, many organizations could spend the next several years operating within the same opaque structures that policymakers are now attempting to correct. Forward-looking benefit leaders should be asking a different question: Why wait for regulation to mandate what can already be implemented strategically today?

Reform Often Confirms What the Market Already Knows 

Federal action rarely appears overnight. It typically follows years of scrutiny, investigation, and mounting concern about systemic practices. 

The FTC’s interim analysis of prescription drug middlemen helped elevate industry awareness around several longstanding issues, including: 

• Limited visibility into rebate flows 
• Potential conflicts within vertically integrated models 
• Incentive structures that may favor higher-cost medications 
• Consolidation among the largest PBMs, increasing their market influence 

For many plan sponsors, these findings validated suspicions they had quietly held for years: the pharmacy supply chain had become increasingly difficult to interpret, and even harder to control. 

The CAA is therefore less of a surprise and more of a directional signal. 

The industry is moving toward transparency because the status quo proved unsustainable. 

What the CAA Signals: Beyond the Policy Language 

While the law focuses heavily on rebate pass-through requirements, disclosure expectations, and audit rights, its broader implication is strategic rather than procedural. It suggests a future pharmacy ecosystem defined by: 

✔ Greater financial clarity 
✔ Stronger fiduciary alignment 
✔ More informed purchasing decisions 
✔ Increased accountability across the supply chain 

However, legislation alone does not guarantee immediate behavioral change. 

Key questions remain: 

• How consistently will these provisions be enforced? 
• How quickly will dominant PBMs adapt their business models? 
• Will new revenue mechanisms emerge as older ones are restricted? 
• How long will it take before employers feel measurable cost impact? 

History suggests that large intermediaries rarely transform overnight. Which makes timing an underappreciated risk. 

The Hidden Cost of Waiting 

For employers and benefit advisors, postponing action until regulatory deadlines arrive can carry meaningful financial consequences. 

Every renewal cycle that passes under a misaligned PBM structure can translate into avoidable spend, limited insight into drug economics, and reduced strategic control. 

By contrast, organizations that prioritize transparency today position themselves to: 

• Strengthen negotiating leverage 
• Improve budget predictability 
• Reduce exposure to hidden revenue streams 
• Better fulfill fiduciary responsibilities 
• Create a more defensible benefits strategy 

In today’s environment, transparency is no longer just a governance issue — it is a competitive advantage.

SHARx: Aligned With Where the Market Is Going 

Long before federal reform entered the conversation, SHARx made a deliberate decision about how pharmacy benefits should function. We partner exclusively with transparent, pass-through PBMs — and historically have never deviated from that standard. 

This was not a reaction to regulatory pressure. It was a proactive commitment grounded in one belief: What most impacts payers and employers should never be obscured. 

As policymakers now push the industry toward greater disclosure, SHARx clients are already operating within that framework. That means: 

• Rebate pass-through structures are already in place 
• Financial arrangements are visible 
• Incentives are aligned with plan outcomes 
• Employers are not waiting years for clarity 

Simply put, the direction regulators are steering the market is the environment SHARx has supported from the beginning. 

Progress Is Good — But Leadership Happens Ahead of Mandates 

The CAA deserves recognition as meaningful progress. Increased transparency has the potential to reshape expectations across the pharmacy landscape and elevate the standard of accountability. 

But sophisticated employers and brokers understand an important truth: 

Regulation typically establishes the floor, not the ceiling. 

Market leaders rarely wait for compliance requirements to dictate strategy. They move early, reduce uncertainty, and align their partners with the future state of the industry. The conversation is no longer just about whether PBM reform is coming; it is about who is already prepared for it. 

The Strategic Takeaway 

The next several years will likely bring continued scrutiny, additional rulemaking, and evolving expectations around pharmacy benefit governance. Organizations that delay action may eventually reach compliance. Organizations that act now can achieve alignment. 

When employers and brokers work with SHARx, they can be confident that the PBMs supporting their strategy already adhere to the transparency and pass-through principles regulators are working to standardize. 

Reform may define where the industry is headed. SHARx helps ensure you are already there.